Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

British Journal of Pharmacology

Volumn 156, Issue 3, 2009, Pages 534-544

  Cortijo, J ^a,b,c   Iranzo, A ^a   Milara, X ^b   Mata, M ^b   Cerda Nicolas M ^a   Ruiz Sauri A ^a   Tenor, H ^d   Hatzelmann, A ^d   Morcillo, E J ^a,c,e  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Nycomed GmbH   (Germany)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Bleomycin; Phosphodiesterase 4 inhibition; Pulmonary fibrosis; Roflumilast; Steroids

Indexed keywords

BLEOMYCIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA; CONNECTIVE TISSUE GROWTH FACTOR; DEXAMETHASONE; ENDOTHELIN 1; HYDROXYPROLINE; LIPID HYDROPEROXIDE; METHYLPREDNISOLONE; MUCIN 5AC; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; LUNG; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DISEASE MODELS, ANIMAL; LUNG; LUNG INJURY; MALE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; PULMONARY FIBROSIS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 65449171997     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00041.x     Document Type: Article

References (47)

1. Ashcroft T, Simpson JM, Timbrell V (1988). Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41 (4 467 470.
2. Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA et al. (2002). Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 27 (4 419 427.
3. Bender AT, Beavo JA (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58 (3 488 520.
4. Boero S, Silvestri M, Sabatini F, Nachira A, Rossi GA (2006). Inhibition of human lung fibroblast functions by roflumilast N-oxide. Eur Respir J 662s : P3845 (abstract).
5. Boswell-Smith V, Page CP (2006). Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opin Investig Drugs 15 (9 1105 1113.
6. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001). In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297 (1 280 290.
7. Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM et al. (2004). Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 45 (5 477 484. (Pubitemid 39524322)
8. Chaudhary NI, Schnapp A, Park JE (2006). Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 173 (7 769 776.
9. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A (2007). Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572 : 12 22.
10. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12 (1 99 106.
11. Gensch E, Gallup M, Sucher A, Li D, Gebremichael A, Lemjabbar H et al. (2004). Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem 279 (37 39085 39093.
12. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D et al. (2007). Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62 (12 1081 1087.
13. Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J (2006). Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 7 : 9.
14. Hatzelmann A, Schudt C (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297 (1 267 279. (Pubitemid 32242587)
15. Hemnes AR, Zaiman A, Champion HC (2008). PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 294 (1 L24 L33.
16. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D et al. (2008). Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther 21 : 616 623.
17. Houslay MD, Schafer P, Zhang KY (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10 (22 1503 1519.
18. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R (2002). Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 83 (3 111 119.
19. Izikki M, Adnot S, Zadigue P, Barlier Mur AM, Maitre B, Raffestin B et al. (2007). Effect of roflumilast on hypoxia-and monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 294s : E1836 (abstract).
20. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ et al. (2001). Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 158 (4 1411 1422.
21. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH et al. (2008). Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 14 (6 633 640.
22. Klar J, Sabatini F, Schatton E, Burgbacher B, Rossi GA, Hatzelmann A et al. (2007). Roflumilast N-oxide reduces human fibroblast function. Eur Respir J 544s : E3258 (abstract).
23. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ et al. (2002). PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26 (6 694 701.
24. Koshika T, Hirayama Y, Ohkubo Y, Mutoh S, Ishizaka A (2005). Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries. Eur J Pharmacol 515 (1-3 169 178.
25. Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M et al. (2003). Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 307 (1 349 355.
26. Le Quement C, Guenon I, Gillon JY, Valenca S, Cayron-Elizondo V, Lagente V et al. (2008). The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 154 : 1206 1215.
27. Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA et al. (2006). COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 291 (2 L144 L156.
28. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005). Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172 (7 848 853.
29. Mata M, Ruiz A, Cerda M, Martinez-Losa M, Cortijo J, Santangelo F et al. (2003). Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur Respir J 22 (6 900 905.
30. Mata M, Sarria B, Buenestado A, Cortijo J, Cerda M, Morcillo EJ (2005). Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 60 (2 144 152.
31. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M (2008). The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40 (3 362 382.
32. Moore BB, Hogaboam CM (2008). Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294 (2 L152 L160.
33. Morcillo EJ, Cortijo J (2006). Mucus and MUC in asthma. Curr Opin Pulm Med 12 (1 1 6.
34. Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ (1998). Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 18 (5 611 619.
35. Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K (2006). In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 61 (10 886 894.
36. O'Neill CA, Giri SN, Wang Q, Perricone MA, Hyde DM (1992). Effects of dibutyrylcyclic adenosine monophosphate on bleomycin-induced lung toxicity in hamsters. J Appl Toxicol 12 (2 97 111.
37. Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW et al. (2002). Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol 282 (6 L1209 L1221.
38. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P (1989). Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170 (3 655 663.
39. Sanz MJ, Cortijo J, Morcillo EJ (2005). PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 106 : 269 297.
40. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M et al. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (10 2811 2821.
41. Serrano-Mollar A, Closa D, Cortijo J, Morcillo EJ, Prats N, Gironella M et al. (2002). P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax 57 (7 629 634.
42. Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, Ueki IF, Nadel JA (2000). Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 164 (3 1546 1552.
43. Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD et al. (2006). Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest 116 (2 309 321.
44. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC et al. (2000). SB239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279 (5 L895 L902.
45. Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D (2008). Therapeutic effect of various PDE4 inhibitors on cigarette smoke-induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med 177 abstract) A652.
46. Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R (2006). Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther 19 (5 343 352.
47. Zhen G, Park SW, Nguyenvu LT, Rodriguez MW, Barbeau R, Paquet AC et al. (2007). IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol 36 (2 244 253.